Emerging drugs for esophageal cancer

Bibliography

• Globocan. International agency for research on cancer. Available from: http://www.dep.iarc.fr 2002
   Google Scholar
• Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):4-66
   PubMed Web of Science ®Google Scholar
• Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29(4):645-54
   PubMed Web of Science ®Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83(10):2049-53
   PubMed Web of Science ®Google Scholar
• Sundelof M, Ye W, Dickman PW, Lagergren J. Improved survival in both histologic types of oesophageal cancer in Sweden. Int J Cancer 2002;99(5):751-4
   PubMed Web of Science ®Google Scholar
• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83(1):18-29
   PubMed Web of Science ®Google Scholar
• Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994;21(4):403-10
   PubMed Web of Science ®Google Scholar
• Lee CH, Lee JM, Wu DC, et al. Carcinogenetic impact of ADH1B and ALDH2 genes on squamous cell carcinoma risk of the esophagus with regard to the consumption of alcohol, tobacco and betel quid. Int J Cancer 2008;122(6):1347-56
   PubMed Web of Science ®Google Scholar
• Cheng KK, Day NE, Duffy SW, et al. Pickled vegetables in the aetiology of oesophageal cancer in Hong Kong Chinese. Lancet 1992;339(8805):1314-8
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993;85(13):1038-49
   PubMed Web of Science ®Google Scholar
• Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 1998;128(2):114-7
   PubMed Web of Science ®Google Scholar
• Sandler RS, Nyren O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA 1995;274(17):1359-62
   PubMed Web of Science ®Google Scholar
• Appelqvist P, Salmo M. Lye corrosion carcinoma of the esophagus: a review of 63 cases. Cancer 1980;45(10):2655-8
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17(3):449-56
   PubMed Web of Science ®Google Scholar
• Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346(11):836-42
   PubMed Web of Science ®Google Scholar
• van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39(1):5-8
   PubMed Web of Science ®Google Scholar
• Cameron AJ. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus 2002;15(2):106-8
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340(11):825-31
   PubMed Web of Science ®Google Scholar
• Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006;3:CD001556
   PubMedGoogle Scholar
• van Heijl M, van Lanschot JJ, Koppert LB, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8(1):21
   PubMedGoogle Scholar
• Hulscher JB, van Sandick JW, Tijssen JG, et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000;191(2):143-8
   PubMed Web of Science ®Google Scholar
• Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347(21):1662-9
   PubMed Web of Science ®Google Scholar
• van Meerten E, van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer 2005;41(5):664-72
   PubMed Web of Science ®Google Scholar
• Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462-7
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086-92
   PubMed Web of Science ®Google Scholar
• Siersema PD, Dees J, van Blankenstein M. Palliation of malignant dysphagia from oesophageal cancer. Rotterdam Oesophageal Tumor Study Group. Scand J Gastroenterol Suppl 1998;225:75-84
   PubMedGoogle Scholar
• Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004;364(9444):1497-504
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Homs MY, Stokvis A, et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005;62(3):333-40
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):12-20
   PubMed Web of Science ®Google Scholar
• Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16(5):1826-34
   PubMed Web of Science ®Google Scholar
• Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994;21(4):474-82
   PubMed Web of Science ®Google Scholar
• Homs MY, v d Gaast A, Siersema PD, et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006;(4):CD004063
   Google Scholar
• Levard H, Pouliquen X, Hay JM, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998;164(11):849-57
   PubMedGoogle Scholar
• Nicolaou N, Conlan AA. Cyclophosphamide, doxorubicin and celestin intubation for inoperable oesophageal carcinoma. S Afr Med J 1982;61(12):428-31
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Norman A, Cunningham D, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002;13(10):1568-75
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15(1):261-7
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20(8):1996-2004
   PubMed Web of Science ®Google Scholar
• Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33(8):1216-20
   PubMed Web of Science ®Google Scholar
• Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980;46(10):2149-53
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses [abstract no. 43]. Gastrointestinal Cancers Symposium 2008
   Google Scholar
• Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005;93(1):107-15
   PubMed Web of Science ®Google Scholar
• Wei Q, Chen L, Sheng L, et al. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007;31(3):493-9
   PubMed Web of Science ®Google Scholar
• Langer R, Von Rahden BH, Nahrig J, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006;59(6):631-4
   PubMed Web of Science ®Google Scholar
• Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67(2):405-9
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007;97(4):494-501
   PubMed Web of Science ®Google Scholar
• Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent? J Pathol 2004;202(1):5-13
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69 (Suppl 3):11-6
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7(6):475-85
   PubMed Web of Science ®Google Scholar
• Lin CC, Papadopoulos KP. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 2007;20(5):365-71
   PubMed Web of Science ®Google Scholar
• Keswani RN, Chumsangsri A, Mustafi R, et al. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus 2008;21(6):514-21
   PubMed Web of Science ®Google Scholar
• Younes M, Georgakis GV, Rahmani M, et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006;42(4):542-7
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14(11):3450-5
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13(20):6187-94
   PubMed Web of Science ®Google Scholar
• Lioni M, Noma K, Snyder A, et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 2008;7(9):2866-75
   PubMed Web of Science ®Google Scholar
• Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53(6):1322-7
   PubMed Web of Science ®Google Scholar
• Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99(7):545-57
   PubMed Web of Science ®Google Scholar
• Kuo KT, Wang HW, Chou TY, et al. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16(2):352-60
   PubMed Web of Science ®Google Scholar
• von Rahden BH, Stein HJ, Hartl SA, et al. Expression of prostaglandin E synthase in Barrett's cancer. Dis Esophagus 2008;21(4):304-8
   PubMed Web of Science ®Google Scholar
• Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70(2):391-5
   PubMed Web of Science ®Google Scholar
• Adenis A, Mariette C, Mirabel X, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran, et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395). Int J Radiat Oncol Biol Phys 2008;72(3):958-9
   PubMed Web of Science ®Google Scholar
• Gold PJ, Goldman B, Iqbal LP, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study [abstract 4536]. J Clin Oncol 2008;26(Suppl)
   PubMed Web of Science ®Google Scholar
• Ku GY, Shah MA, Tang LH, et al. Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer [abstract 15580]. J Clin Oncol 2008;26(Suppl)
   Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24(10):1612-9
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Rybicki LA, Carroll MA, et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer [abstract 4054]. J Clin Oncol 2005;23(16S)
   Web of Science ®Google Scholar
• Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13(19):5869-75
   PubMed Web of Science ®Google Scholar
• Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 2008;31(4):329-34
   PubMed Web of Science ®Google Scholar
• Sunpaweravong P, Sunpaweravong D, Sangthawan D, et al. Combination of gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma [abstract 4605]. J Clin Oncol 2007;25(18S)
   Google Scholar
• Tew WP, Shah M, Schwartz G, et al. Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer [abstract no. 5]. Gastrointestinal Cancers Symposium 2005
   Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24(30):4922-7
   PubMed Web of Science ®Google Scholar
• Dobelbower MC, Russo SM, Raisch KP, et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006;17(1):95-102
   PubMed Web of Science ®Google Scholar
• Safran H, DiPetrillo T, Nadeem A, et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22(5):670-7
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201-6
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer [abstract no. 68]. Gastrointestinal Cancers Symposium 2006
   Google Scholar
• Shah MA, Holen K, Singh D, et al. A Multicenter, two-stage, Phase II study of PS-341 in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma [abstract no. 41]. Gastrointestinal Cancers Symposium 2005
   Google Scholar
• Jatoi A, Dakhil SR, Foster NR, et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008;3(5):516-20
   PubMed Web of Science ®Google Scholar
• Vervenne WL, Bollen JM, Bergman JJ, et al. Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer [abstract no. 4054]. J Clin Oncol 2004;22(14S)
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Michael M, Biagi J, et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007;25(2):123-9
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mamon H, Choi N, et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer [abstract no. 35]. Gastrointestinal Cancers Symposium 2004
   Google Scholar
• Govindan R, McLeod H, Mantravadi P, et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park) 2004;18(14 Suppl 14):18-21
   PubMedGoogle Scholar